SwitzerlandSwitzerland

Mondobiotech in merger negotiations with Pierrel

05.03.2012

Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and life science industries, Pierrel SpA, with regard to a potential combination of the Contract Research Organization (CRO) of Pierrel with Mondobiotech. According to a non-binding letter of intent signed by the parties, the business combination should be structured by way of a contribution in kind of 100% of the share capital of Pierrel Research International AG (the CRO holding company), fully owned by Pierrel into the capital of Mondobiotech, through a dedicated capital increase of the latter. The news led initially to a Mondobiotech share price rally at the SIX Swiss Exchange to a plus of 88 % (at 0.75 CHF) before falling back to 0.40 CHF. Last December, Mondobiotech announced that, due to the current financial market conditions and the lack of significant progress with currently available options, it would be implementing restructuring measures. Together with other fluctuations, this would include a reduction of more than 50% of the firm’s total workforce by the end of February 2012. Activities will be concentrated in the company’s Stans headquarters.

SwitzerlandSwitzerland

03.06.2011

Basel/Würzburg – Scientists from Swiss Novartis AG have cracked the mechanism that leads to permanent activation of the immune system in course of atherosclerosis and have targeted an antibody against it in mice and humans (JCI,...

SwitzerlandSwitzerland

27.05.2011

Basel - Scientists at Roche Holding AG's subsidiary Genentech have found a way to get antibodies across the blood-brain barrier that block the enzyme beta-secretase 1 which is believed to prevent formation of Alzheimer's plaques....

SwitzerlandSwitzerland

24.05.2011

Allschwil – Swiss biotech firm Actelion Pharma has reached the primary endpoint of preventing allergic rhinitis symptoms in patients challenged with Mountain Cedar pollen in a proof-of-concept study with its oral CRTH2...

SwitzerlandSwitzerland

13.05.2011

Basel – Swiss drugmaker Roche has filed for MAA in Europe and the U.S. for vemurafenib (RG7204, PLX4032 , RO5185426) in patients with malignant melanoma who carry the common B-Raf V600E mutation. The oral B-RAF blocker interrupts...

SwitzerlandSwitzerland

20.04.2011

Basel – Novartis COPD drug NVA237 (glycopyrronium bromide) has met the primary endpoint of superior bronchodilation to placebo at 12 weeks in a Phase III study with 800 participants, according to the Swiss drug giant’s...

SwitzerlandSwitzerland

15.04.2011

Zurich – Researchers under Prof Dario Neri from ETH Zurich have presented a new approach that cured squamous cell carcinoma in two mouse models (Br. J Cancer, doi: 10.1038/bjc.12.04.11). The founder of the biotech firm Philogen,...

SwitzerlandSwitzerland

12.04.2011

Zurich – Swiss Novartis AG has discontinued a Phase III head-to-head comparison of Tasigna (nilotinib) with the company’s US-$4 million blockbuster Glivec (imatinib) as first-line treatment of gastrointestinal stromal tumours...

Displaying results 41 to 50 out of 276

< Previous 41-50 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/4/article/mondobiotech-in-merger-negotiations-with-pierrel.html

Product of the week

Products

Events

All Events

Current issue

All issues